采用胜率法评估艾多沙班对比达肝素治疗癌症相关静脉血栓栓塞症:随机Hokusai静脉血栓栓塞症癌症试验分析
本研究对Hokusai静脉血栓栓塞症癌症试验进行胜率法再分析,由49名血栓专家对10项结局按临床重要性排序,在6个月和12个月对艾多沙班组与达肝素组进行非匹配配对比较。12个月胜率为0.91(95%CI 0.76-1.08),胜差为-3.55%(95%CI -9.9%至2.9%),6个月胜率同为0.91(95%CI 0.75-1.11),未观察到显著差异。
要点
- 12个月胜率0.91(95%CI 0.76-1.08),胜差-3.55%(95%CI -9.9%至2.9%),无显著差异。
- 6个月胜率0.91(95%CI 0.75-1.11),与12个月结果一致。
- 仅按死亡、复发性VTE和大出血分层时胜率0.92(95%CI 0.76-1.11),结论一致。
核心结论
- 采用10项优先结局分层的胜率法分析,艾多沙班与达肝素治疗癌症相关静脉血栓栓塞症未观察到显著差异。
研究设计与样本
- 对随机Hokusai静脉血栓栓塞症癌症试验的再分析,49名血栓专家将10项结局从全因死亡(最重要)到临床相关非大出血(最不重要)排序。
- 在6个月和12个月随访时对艾多沙班组与达肝素组参与者进行非匹配配对比较,共273528对(522×524名参与者)。
- 每对中根据结局分层将艾多沙班判定为胜、负或平,计算胜率(艾多沙班患者总胜数除以总负数)和胜差(总胜数减总负数)。
主要发现
- 12个月时,艾多沙班胜率34.9%、负率38.5%、平率26.6%。
- 12个月胜率为0.91(95%CI 0.76-1.08),胜差为-3.55%(95%CI -9.9%至2.9%)。
- 6个月胜率仍为0.91(95%CI 0.75-1.11)。
- 仅按死亡、复发性VTE和大出血分层时胜率为0.92(95%CI 0.76-1.11)。
- 将全因死亡替换为VTE相关死亡或致死性出血时胜率为0.83(95%CI 0.65-1.06)。
关键数值与推荐
- 胜率分析中,胜率大于1(胜多于负)提示艾多沙班获益,胜率为0.91(95%CI 0.76-1.08)未达统计学显著。
- 胜差为-3.55%(95%CI -9.9%至2.9%),95%CI跨0,未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Hokusai Venous Thromboembolism (VTE) Cancer trial demonstrated that edoxaban was noninferior to dalteparin for the treatment of cancer-associated venous VTE. OBJECTIVES: We reanalyzed the trial using the win ratio, an approach that evaluates a composite of outcomes in a hierarchical order. METHODS: Forty-nine thrombosis experts ranked 10 outcomes in order of clinical importance from all-cause death (most important) to clinically relevant nonmajor bleeding (least important). We performed unmatched pairwise comparisons between participants on edoxaban and those on dalteparin at 6- and 12-month follow-up. Within each pair, edoxaban was assigned a win, loss, or tie according to the hierarchy of outcomes. We calculated the win ratio (total wins divided by total losses among edoxaban patients), with more wins than losses indicating the benefit of edoxaban, and the win difference (total wins minus total losses). RESULTS: Among 273 528 pairs (522 × 524 participants), edoxaban was associated with a win in 34.9%, a loss in 38.5%, and a tie in 26.6%. The win ratio was 0.91 (95% CI, 0.76-1.08), with a win difference of -3.55% (95% CI, -9.9% to 2.9%) at 12 months. The win ratio remained unchanged at 6 months (0.91; 95% CI, 0.75-1.11). The findings were consistent with a hierarchy of only death, recurrent VTE, and major bleeding (win ratio, 0.92; 95% CI, 0.76-1.11), or when replacing all-cause death with VTE-related death or fatal bleeding (win ratio, 0.83; 95% CI, 0.65-1.06). CONCLUSION: We observed no significant difference between edoxaban and dalteparin for the treatment of cancer-associated VTE when using the win ratio approach with a hierarchy of 10 prioritized outcomes.
引用
- van Es N, Scheres LJJ, Sanfilippo KM, et al. The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial. J Thromb Haemost. 2025. PMID: 41422947. doi:10.1016/j.jtha.2025.11.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。